| Clone: | MEM-15 |
|---|---|
| Isotype: | Mouse IgG1 |
| Specificity: | The antibody MEM-15 reacts with CD14, a 53-55 kDa GPI (glycosylphosphatidylinositol)-linked membrane glycoprotein expressed on monocytes, macrophages and weakly on granulocytes; also expressed by most tissue macrophages. The antibody MEM-15 also reacts with soluble forms of CD14 found in serum and in the urine of some nephrotic patients. HLDA III; WS Code M 252 HLDA IV; WS Code M 113 HLDA IV; WS Code NL 90 HLDA IV; WS Code T 53 HLDA V; WS Code M MA086 HLDA VI; WS Code M MA94 |
| Immunogen: | A crude mixture of human urinary proteins precipitated by ammonium sulphate from the urine of a patient suffering from proteinuria. |
| Species Reactivity: | Human, Non-Human Primates |
| Application: |
Flow Cytometry
Recommended dilution:4 μg/ml
Immunoprecipitation
excellent for immunoprecipitation of CD14
|
| Purity: | > 95% (by SDS-PAGE) |
| Purification: | Purified from ascites by protein-A affinity chromatography. |
| Concentration: | 1 mg/ml |
| Storage Buffer: | Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4 |
| Storage / Stability: | Store at 2-8°C. Do not use after expiration date stamped on vial label. For long-term storage aliquot and store at -20°C. Avoid freeze/thaw cycles. |
| Expiration: | See vial label |
| Lot Number: | See vial label |
| Background: | CD14 is a 55 kDa GPI-anchored glycoprotein, constitutively expressed on the surface of mature monocytes, macrophages, and neutrophils, where serves as a multifunctional lipopolysaccharide receptor; it is also released to the serum both as a secreted and enzymatically cleaved GPI-anchored form. CD14 binds lipopolysaccharide molecule in a reaction catalyzed by lipopolysaccharide-binding protein (LBP), an acute phase serum protein. The soluble sCD14 is able to discriminate slight structural differences between lipopolysaccharides and is important for neutralization of serum allochthonous lipopolysaccharides by reconstituted lipoprotein particles. CD14 affects allergic, inflammatory and infectious processes. |
| References: |
*Juan TS, Hailman E, Kelley MJ, Wright SD, Lichenstein HS: Identification of a domain in soluble CD14 essential for lipopolysaccharide (LPS) signaling but not LPS binding. J Biol Chem. 1995 Jul 21;270(29):17237-42.
*Fernández-Real JM, Broch M, Richart C, Vendrell J, López-Bermejo A, Ricart W: CD14 monocyte receptor, involved in the inflammatory cascade, and insulin
sensitivity. J Clin Endocrinol Metab. 2003 Apr;88(4):1780-4.
*Lodrup Carlsen KC, Granum B: Soluble CD14: role in atopic disease and recurrent infections, including otitis
media. Curr Allergy Asthma Rep. 2007 Nov;7(6):436-43.
*Asai Y, Makimura Y, Kawabata A, Ogawa T: Soluble CD14 Discriminates Slight Structural Differences between Lipid As That Lead to Distinct Host Cell Activation. J Immunol. 2007 Dec 1;179(11):7674-83.
*Bazil V, Horejsi V, Baudys M, Kristofova H, Strominger JL, Kostka W, Hilgert I.: Biochemical characterization of a soluble form of the 53-kDa monocyte surface
antigen. Eur J Immunol. 1986 Dec;16(12):1583-9.
*Leukocyte Typing III., McMichael A. J. et al (Eds.), Oxford University Press (1987).
*Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989).
*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).
*Funda DP, Tucková L, Farré MA, Iwase T, Moro I, Tlaskalová-Hogenová H: CD14 is expressed and released as soluble CD14 by human intestinal epithelial cells in vitro: lipopolysaccharide activation of epithelial cells revisited. Infect Immun. 2001 Jun;69(6):3772-81.
*Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, Kirschning CJ, Aepfelbacher M, Heesemann J: Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med. 2002 Oct 21;196(8):1017-24.
*Schiff DE, Rae J, Martin TR, Davis BH, Curnutte JT: Increased phagocyte Fc gammaRI expression and improved Fc gamma-receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood. 1997 Oct 15;90(8):3187-94.
|
For laboratory research only, not for drug, diagnostic or other use. EXBIO Praha | Nad Safinou II 341 | 252 42 Vestec u Prahy | Czech Republic Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz |